Eczema Treatment Guidelines

Introduction to Eczema Management

The American Academy of Dermatology recommends avoiding injectable methylprednisolone for eczema treatment, as systemic corticosteroids do not induce stable remission and frequently cause rebound flares upon discontinuation 1, 2
Systemic corticosteroids have a limited role only for "tiding over" occasional patients during acute severe crises after all other treatment options have been exhausted, including optimized topical corticosteroids, emollients, infection management, and second-line treatments 2

Apply high-potency or ultra-high potency topical corticosteroids twice daily to affected areas for up to 2 consecutive weeks maximum (not exceeding 50g per week) 1
Combine with aggressive emollient therapy applied immediately after bathing to restore the epidermal barrier 1
Add dilute bleach baths (0.005% sodium hypochlorite) twice weekly if the patient has a history of recurrent staphylococcal infections 1

Watch for overt secondary bacterial infection (crusting, weeping, pustules) and treat with oral flucloxacillin as first-line therapy for Staphylococcus aureus 1, 2
Continue topical corticosteroids during bacterial infection when appropriate systemic antibiotics are given concurrently—do not withhold them 1, 2
Suspect eczema herpeticum if you observe grouped vesicles, punched-out erosions, or sudden deterioration with fever—this is a medical emergency requiring immediate oral or intravenous acyclovir 4, 2

Phototherapy (narrowband UVB) is the next step for severe eczema refractory to optimized topical treatments, with strong evidence for efficacy 1
Topical calcineurin inhibitors can be used as steroid-sparing agents, particularly for sensitive areas like the face 1
Cyclosporine (2.7-4.0 mg/kg daily) should be the first systemic agent considered for severe adult eczema, as it is significantly more efficacious than prednisolone for inducing stable remission 1

Systemic steroids should not be used for maintenance treatment because they fail to induce stable remission and lead to disease rebound after discontinuation 1, 2
Pituitary-adrenal suppression is a significant risk with systemic corticosteroid use, particularly concerning in children where growth interference can occur 3
Do not use systemic steroids as maintenance therapy—they create a cycle of dependency and rebound flares 1, 2
Do not withhold topical corticosteroids when infection is present—they remain the primary treatment when appropriate antibiotics are given 1, 2